Citizens Jmp Issues Pessimistic Forecast for argenex (NASDAQ:ARGX) Stock Price

argenex (NASDAQ:ARGX) had its target price dropped by stock analysts at Citizens Jmp from $944.00 to $932.00 in a note issued to investors on Friday,Benzinga reports. The firm currently has a “market outperform” rating on the stock. Citizens Jmp’s price objective suggests a potential upside of 1.50% from the stock’s previous close.

Several other research firms have also recently weighed in on ARGX. Royal Bank Of Canada lifted their target price on argenex from $890.00 to $945.00 and gave the company an “outperform” rating in a research note on Tuesday, July 7th. Wells Fargo & Company increased their price target on shares of argenex from $1,260.00 to $1,291.00 and gave the stock an “overweight” rating in a research report on Monday, June 1st. Oppenheimer decreased their price target on shares of argenex from $1,060.00 to $1,014.00 and set an “outperform” rating for the company in a report on Thursday, April 2nd. Glj Research raised shares of argenex to a “strong-buy” rating in a research report on Friday, April 3rd. Finally, Guggenheim upped their price objective on shares of argenex from $1,120.00 to $1,135.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $1,050.50.

argenex Trading Down 0.7%

Shares of ARGX stock opened at $918.22 on Friday. The company has a market capitalization of $57.44 billion, a price-to-earnings ratio of 35.26, a P/E/G ratio of 1.13 and a beta of 0.45. argenex has a 1-year low of $587.37 and a 1-year high of $953.58. The stock’s fifty day simple moving average is $868.28 and its 200-day simple moving average is $815.12.

argenex (NASDAQ:ARGX) last announced its quarterly earnings data on Tuesday, July 21st. The company reported $7.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.86 by $1.46. The firm had revenue of $1.54 billion during the quarter, compared to the consensus estimate of $1.45 billion. argenex had a return on equity of 70.27% and a net margin of 32.19%. On average, sell-side analysts predict that argenex will post 26.95 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Sound Income Strategies LLC acquired a new position in argenex in the 4th quarter worth about $28,000. Whipplewood Advisors LLC acquired a new stake in shares of argenex during the 1st quarter valued at about $28,000. Eastern Bank acquired a new stake in shares of argenex during the 2nd quarter valued at about $32,000. Sunbelt Securities Inc. bought a new stake in shares of argenex in the 3rd quarter valued at approximately $36,000. Finally, Axiom Investment Management LLC bought a new stake in shares of argenex in the 1st quarter valued at approximately $50,000. Hedge funds and other institutional investors own 60.32% of the company’s stock.

Key Stories Impacting argenex

Here are the key news stories impacting argenex this week:

• Positive Sentiment: argenex reported Q2 EPS of $7.32, topping estimates, on revenue of $1.54 billion versus expectations of $1.45 billion, highlighting strong operating momentum and profitability. Q2 earnings report and conference call
• Positive Sentiment: Reuters reported that global sales of Vyvgart jumped in the second quarter, a key driver for argenex’s growth and a major reason the stock has been gaining investor attention. Reuters article on Vyvgart sales
• Positive Sentiment: Oppenheimer, RBC, and Guggenheim all raised price targets and maintained bullish ratings, signaling increased Street confidence in argenex’s growth trajectory and pipeline prospects.
• Positive Sentiment: A Seeking Alpha note highlighted surging profitability, robust cash generation, and operational leverage, while pointing to pipeline catalysts such as empasiprubart as additional upside potential. Seeking Alpha rating upgrade article
• Neutral Sentiment: Short-interest data showed 0 shares reported, which provides little actionable signal for investors because the figures appear unchanged and unusually low.
• Negative Sentiment: Citizens JMP trimmed its price target slightly from $944 to $932, though it still kept a positive rating, making this more of a minor caution than a bearish call.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.